evaluation of use of 3% sodium tetradecyl sulphate and 25% dextrose in the treatment of temporomandibular joint hypermobilty
Phase 2
- Conditions
- Health Condition 1: K089- Disorder of teeth and supporting structures, unspecifiedHealth Condition 2: M266- Temporomandibular joint disorders
- Registration Number
- CTRI/2023/08/056023
- Lead Sponsor
- Dr Pimple Subham
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients diagnosed with functional temporomandibular joint disorders including Internal Derangement, Subluxation and Dislocation.
2.Patients who are willing to participate in the study and give their consent
Exclusion Criteria
1. Subjects under Anticoagulation therapy
2. Subjects with a History of total TMJ replacement,
3. Subjects with a Prior TMJ prolotherapy in the past 6 months
4. Subjects with TMJ injection within the past 3 months
5. Patients with concomitant inflammatory or infectious disorders of the TMJ
6. Patients with Daily use of opioid medication
7. Patients with Allergy or intolerance to study injections or pain medications
8. Patients with Connective tissue disorders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method EVALUATION OF EFFICACY OF 3% SODIUM TETRADECYL SULPHATE AND 25% DEXTROSE IN TREATMENT OF TEMPOROMANDIBULAR JOINT HYPERMOBILITYTimepoint: 18 MONTHS
- Secondary Outcome Measures
Name Time Method to determine the better treatment intervention between 25% dextrose prolotherapy and 3% sodium tetradecyl sulphateTimepoint: 18 months